BACKGROUND: Intermediate end points are desirable to expedite the integration of neoadjuvant systemic therapy into the treatment strategy for high-risk localized prostate cancer. Endorectal magnetic resonance imaging at 1.5 Tesla (1.5T erMRI) response has been utilized as an end point in neoadjuvant trials but has not been correlated with clinical outcomes. METHODS: Data were pooled from two trials exploring neoadjuvant chemotherapy in high-risk localized prostate cancer. Trial 1 explored docetaxel for 6 months and Trial 2 explored docetaxel plus bevacizumab for 4.5 months, both before radical prostatectomy. erMRI was done at baseline and end of chemotherapy. 1.5T erMRI response, based upon T2W sequences, was recorded. Multivariable Cox regression was undertaken to evaluate the association between clinical parameters and biochemical recurrence. RESULTS: There were 53 evaluable patients in the combined analysis: 20 (33%) achieved a PSA response, 16 (27%) achieved an erMRI partial response and 24 (40%) achieved an erMRI minor response. Median follow-up was 4.2 years, and 33 of 53 evaluable (62%) patients developed biochemical recurrence. On multivariable analysis, PSA response did not correlate with biochemical recurrence (hazard ratio ¼ 0.58, 95% confidence interval (CI) 0.25-1.33) and paradoxically erMRI response was associated with a significantly shorter time to biochemical recurrence (hazard ratio ¼ 2.47, 95% CI 1.00-6.13). CONCLUSIONS: Response by 1.5T erMRI does not correlate with a decreased likelihood of biochemical recurrence in patients with high-risk localized prostate cancer treated with neoadjuvant docetaxel and may be associated with inferior outcomes. These data do not support the use of 1.5T erMRI response as a primary end point in neoadjuvant chemotherapy trials.
INTRODUCTION
Prostate cancer is the most common cancer diagnosed in men in the United States. 1 In the 'PSA-era', the vast majority of patients with prostate cancer present with clinically localized disease and are cured with surgery or radiation, or may even be safely monitored without immediate intervention on surveillance protocols. 2, 3 However, a subset of men with clinically localized prostate cancer harbor micrometastases, and ultimately relapse despite local therapy, contributing to over 30 000 prostate cancer deaths per year in the United States alone. 1 Clinico-pathologic features have been identified that may be utilized to identify this high-risk group of men. [4] [5] [6] [7] Thus, several groups have explored the integration of neoadjuvant chemotherapy, before radical prostatectomy, in an attempt to improve the outcomes of these patients. [8] [9] [10] Intermediate end points, events or biomarkers that are early precursors to a given health outcome, are highly desirable in expediting the development of neoadjuvant approaches in prostate cancer. Intermediate end points need not necessarily fulfill the statistical criteria for 'surrogacy' 11 to be useful in screening the activity of novel therapies and prioritizing regimens for further testing. Such end points, when applied in the phase II setting, can help inform critical decisions regarding the initiation of large and expensive definitive phase III trials. Though complete pathologic response has served as an important intermediate end point in phase II neoadjuvant trials in other solid tumors, 12 pathologic complete responses have historically been rarely achieved in prostate cancer. Alternatively, most patients with high-risk localized prostate cancer have an elevated serum PSA, and measurable tumor lesions on endorectal magnetic resonance imaging (erMRI), and post-treatment changes in these variables can be readily assessed.
We have previously completed sequential trials of neoadjuvant docetaxel-based chemotherapy before radical prostatectomy in patients with high-risk localized prostate cancer. 10, 13 Both trials integrated baseline and post-treatment erMRI measurements prospectively as an end point. In the current analysis, we have explored the prognostic significance of post-treatment changes in erMRI measurements and PSA, to generate further support for the use of these parameters as intermediate end points in future neoadjuvant trials.
MATERIALS AND METHODS

Patient population
Data from two prospective phase II trials of docetaxel-based neoadjuvant chemotherapy administered before radical prostatectomy in patients with high-risk clinically localized prostate cancer were pooled for the current analysis. The full details of both trials have previously been published. 10 
Outcome assessments
Patients enrolled on Trial 1 underwent an erMRI at baseline and after 2 months of therapy. Provided there was no evidence of disease progression on T2W sequences, patients continued on treatment and underwent a repeat erMRI after completion of neoadjuvant chemotherapy (B6 months after initiation of chemotherapy). On Trial 2, patients underwent an erMRI at baseline and again after completing six cycles of neoadjuvant chemotherapy (B4.5 months after initiation of chemotherapy).
Tumor size was calculated as follows: on the baseline erMRI, one target prostate cancer lesion was identified. This lesion was identified on multiplanar T2 weighted imaging. The target lesion was identified as the largest of the lesions in the prostate and was ideally 40.5 mm 3 . The target lesion was measured and recorded by its longest diameter in three dimensions to derive a volumetric measurement. Two independent radiologists centrally reviewed all erMRIs, blinded to clinical outcome, on Trial 1. On Trial 2, 36/41 patients enrolled (all patients at Dana Farber Cancer Center) had erMRIs reviewed by a single study radiologist, blinded to clinical outcome.
On Trial 1, serum PSA measurements were obtained at baseline and monthly during neoadjuvant chemotherapy. On Trial 2, serum PSA measurements were obtained at baseline and on day 1 of each neoadjuvant chemotherapy cycle (every 3 weeks).
Statistical design
This primary objective of this analysis was to evaluate the association between erMRI response and clinical outcome (biochemical recurrence), in patients with high-risk localized prostate cancer treated with docetaxelbased neoadjuvant therapy. Only patients that underwent radial prostatectomy were included in the analysis.
erMRI response was categorized as a partial response (450% decline for the largest lesion during chemotherapy), a minor response (25-50% decline) or no response. PSA response was defined as 450% decline in PSA compared with baseline. Biochemical recurrence was defined as the first PSA X0.2 ng ml À (confirmed by subsequent PSA X0.2) or date of initiation of new therapy (including salvage RT or hormonal therapy) postradical prostatectomy. Patients without evidence of biochemical recurrence were censored at last follow-up for disease. Overall survival was defined as the time from date of surgery until date of death or last followup for survival.
Fisher exact test was used to evaluate the association between erMRI and PSA response. The distribution and median time to biochemical recurrence were estimated using the Kaplan-Meier methodology; comparison between groups was conducted using the log-rank test or a stratified log-rank test. Hazard ratios and 95% confidence intervals (CIs) were estimated from Cox regression and Wald w 2 -tests were reported. Multivariable Cox regression was also undertaken to adjust for patient and disease characteristics in the comparison of erMRI response.
RESULTS
Patient, treatment and tumor characteristics
The patient characteristics are outlined in Table 1 Table 2 . The erMRI response rate (partial response þ minor response) was 67% in patients who did not achieve a PSA response and was 70% in PSA responders (P ¼ 0.99). In Trial 1, PSA responders had a lower erMRI response rate (64% vs 86%), while Trial 2 showed an opposite trend (78% vs 63%). None of these comparisons were statistically significant (PX0.40). There was no clear relationship between achieving a PSA and erMRI response.
Biochemical recurrence and survival
The median follow-up post-radical prostatectomy for Trial 1 was 8.7 years (range, 0.1-11.9 years), for Trial 2 was 3.5 years (range, 0.8-5.3 years) and for the combined cohort was 4.2 years (range, 0.1-11.9 years). Among the 53 patients that underwent radical prostatectomy, 62% (33/53) developed a biochemical recurrence. The median time to biochemical recurrence from the date of surgery was 2.2 years (95% CI: 1.0-4.4 years). There were five deaths at time of the analysis (all five patients had developed biochemical recurrence). Four deaths were due to prostate cancer and one was from relapsed esophageal cancer. The median overall survival post-surgery has not been reached. The survival rate was 92% (95% CI: 77-98%) at 5 years and 71% (36-89%) at 10 years post-radical prostatectomy.
Association between response measures and biochemical recurrence The results of the univariable analysis correlating erMRI and PSA response with biochemical recurrence are shown in Table 3 . There were trends observed for longer time to biochemical recurrence in patients achieving a PSA response and in patients not achieving Figure 1 .
erMRI in prostate cancer MD Galsky et al an erMRI response. When patients were classified into four groups based on erMRI and PSA response, patients with erMRI response but lacking PSA response had the poorest outcome. However, these associations did not reach statistical significance. Of note, a higher proportion of patients with Gleason scores 47 or T3 stage disease achieved an erMRI response, although these associations did not reach statistical significance (data not shown).
The association between erMRI response and time to biochemical recurrence was subsequently explored in multivariable models adjusted for baseline tumor characteristics. Two multivariable models were constructed as shown in Table 4 . We did not detect a significant association between PSA response and the time to biochemical recurrence (hazard ratio ¼ 0.58, 95% CI 0.25-1.33, P ¼ 0.20). However, both models revealed that an erMRI response was paradoxically associated with a shorter time to biochemical recurrence.
DISCUSSION
Intermediate end points could potentially speed the development of neoadjuvant therapeutic approaches for the treatment of high-risk clinically localized prostate cancer by providing a basis for screening the activity of novel regimens in the phase II setting and prioritizing regimens for definitive investigation. Although intermediate end points need not necessarily fulfill the criteria of 'surrogacy' 11 to prove useful, such measures should demonstrate an association with the ultimate health outcome of interest. In the current analysis, we explored two potential intermediate end points utilized in trials of neoadjuvant docetaxel. Post-treatment declines in PSA were not significantly associated with biochemical recurrence on univariable or multivariable analysis, though trends were observed which did not reach statistical significance possibly due to the small sample size. Paradoxically, erMRI response did not correlate with prolonged time to biochemical recurrence and, in fact, may be associated with worse outcomes.
The potential reason for the paradoxical association between erMRI response and biochemical recurrence is not entirely clear. One possible explanation may be related to a higher likelihood of objective regressions in more highly proliferative and/or aggressive primary tumor lesions. Chemotherapy may be sufficient to shrink such tumors, though treatment is clearly insufficient to eradicate these tumors (as evidenced by the lack of complete pathologic responses) and may, likewise, be insufficient to eradicate micrometastatic disease. While this is purely speculative, a higher proportion of patients in the current analysis with Gleason 47 disease achieved an erMRI response, though this association did not reach statistical significance. Post-treatment decrease in tumor volume on MRI has been associated with prolonged time to recurrence in other tumors, such as breast cancer.
14 However, these disparate results may be related to the increased likelihood of achieving 'deeper' tumor regressions (for example, complete pathologic responses) in breast cancer compared with prostate cancer.
There are several limitations to the current study. This is a retrospective analysis though the erMRI measurements and PSA's were collected prospectively in the respective trials. The sample size is relatively small and involved pooling two trials with similar, though not identical, characteristics. However, to our knowledge, this is the first analysis exploring the correlation between erMRI and/or PSA changes after neoadjvant chemotherapy and longterm clinical outcomes in prostate cancer. The majority of patients in the current analysis received bevacizumab in combination with docetaxel and the degree to which this regimen, impacting the tumor neovasculature, may impact the measurement of tumor volume on MRI independently of actual tumor regressions is unclear. The current analysis correlated post-treatment changes in erMRI and PSA with biochemical recurrence, rather than overall survival, given the small number of deaths in the cohort. However, the vast majority of patients that die because of prostate cancer first experience biochemical recurrence, and biochemical recurrence is particularly ominous in this population of patients with poor baseline prognostic features. 15 Given these limitations, the findings of the current analysis should ultimately be validated in an independent cohort.
Another important limitation is the MRI technique itself. The MRI techniques employed in these studies are no longer state of the art. Since 2007 to 2009, two major changes have occurred in prostate MRI that were not available for these protocols. The use of 3T magnets, which allow higher signal to noise ratios, have lead to improvements in characterization of individual lesions within the gland. Perhaps more importantly is the lack of diffusion sequences (diffusion weighted imaging). The diffusion weighted imaging, and the accompanying attenuation diffusion coefficient values, has had a major impact on MRI. The attenuation diffusion coefficient values have been shown to not only improve focal lesion detection but have even shown correlations with Gleason grade. [16] [17] [18] [19] Whether the availability of these technological advances would have altered the outcome of the current analysis can only be speculated upon, although future studies with next-generation imaging techniques are warranted.
The results of this analysis may only apply to neoadjuvant trials exploring cytotoxic chemotherapy. Recently, the use of novel hormonal regimens in the neoadjuvant setting has yielded more impressive tumor regressions including a subset of patients achieving near, and even complete, pathologic responses. 20, 21 These major pathologic responses may not only represent superior intermediate end points for neoadjuvant prostate cancer trials, but will also ultimately need to be correlated with long-term clinical outcomes. The degree to which erMRI changes may better correlate with long-term outcomes in the context of these more active neoadjuvant regimens also warrants investigation.
The current analysis reveals that 1.5T erMRI response on T2 weighted images does not correlate with a longer time until biochemical recurrence in patients with high-risk localized prostate cancer treated with neoadjuant docetaxel-based therapy, and may be associated with inferior clinical outcomes. These findings do not support the use of erMRI response, utilizing the techniques employed in these studies, as a primary end point in future trials of neoadjuvant chemotherapy in prostate cancer. However, more active recently developed neoadjuvant hormonal therapy regimens may finally allow the exploration of major pathologic responses as intermediate end points in this clinical disease state, expediting the integration of multimodality approaches for high-risk localized disease. In addition, prospective studies should continue to integrate next-generation imaging technologies, as secondary outcome measures, in an effort to develop non-invasive intermediate end points.
